FDA approves milnacipran

Forest (NYSE:FRX) and Cypress (NASDAQ:CYPB) said late Wednesday that FDA approved an NDA for Savella milnacipran for fibromyalgia. The partners expect to launch the norepinephrine and serotonin reupta...